Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,055.30 +36.91 (+0.74%) Dow
38,169.46 +266.17 (+0.70%) Nasdaq
15,804.15 +198.67 (+1.27%) Bitcoin USD
59,214.18 +1,400.04 (+2.42%) CMC Crypto 200
1,277.02 +6.28 (+0.49%)
AB Science S.A. (ABSCF)
| Previous close | 2.7000 |
| Open | 2.7000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.7000 - 2.7000 |
| 52-week range | 2.5500 - 9.0000 |
| Volume | |
| Avg. volume | 1,303 |
| Market cap | 133.71M |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3900 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
PRESS RELEASE THE PARIS COURT OF APPEAL CONFIRMS THE ACQUITTAL OF THE CEO OF AB SCIENCE, ALAIN MOUSSY, AND REDUCES THE AMOUNT OF THE FINANCIAL PENALTY IMPOSED ON AB SCIENCE Paris, May 2, 2024, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) and the Chairman of the French market regulator (Autorité des Marchés Financiers - AMF) had filed an appeal to the Paris Court of Appeal against the decision of the AMF Sanctions commission, dated March 24, 2022, which acquitted Alain Moussy, CEO of AB S
- GlobeNewswire
AB Science announces a slight delay in the publication of its 2023 annual financial report
PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2023 ANNUAL FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS 2023 ANNUAL FINANCIAL REPORT NO LATER THAN 15 MAY 2024 Paris, April 30 2024, 6.30pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2023 annual financial report, initially scheduled for 30 April 2024, to give the auditors time to complete their audit work. The Company will publish its 2023 annual financ
- GlobeNewswire
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED ELIGIBILITY FOR RECONSIDERATION REQUEST FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Paris, 3 April, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS). The reconsideration process will re-examine, with new assessors, the decision based on information that was included in the origina
